Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
Phase 2
Completed
- Conditions
- Nasopharyngeal Cancer
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 263
- Registration Number
- NCT03175939
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1
Withdrawn
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Carcinoma, Squamous CellOral CancerLarynx CancerOropharynx CancerLip CancerEsophageal Cancer
- Interventions
- Drug: DurvalumabDrug: CarboplatinDrug: Nab-paclitaxelProcedure: Surgical resectionDrug: CisplatinRadiation: IMRT
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03174275
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineBiological: CetuximabDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelBiological: nivolumabDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: avelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Merkel Cell Carcinoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-051Biological: ETBX-061Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167164
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Melanoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-paclitaxelBiological: NivolumabDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167177
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Stage IA Lung Non-Small Cell Carcinoma AJCC v7Stage IB Lung Non-Small Cell Carcinoma AJCC v7Stage II Lung Non-Small Cell Cancer AJCC v7Stage I Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIA Lung Non-Small Cell Carcinoma AJCC v7Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
- Interventions
- Biological: IpilimumabDrug: CarboplatinDrug: CisplatinBiological: NivolumabDrug: DocetaxelDrug: Pemetrexed
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 101
- Registration Number
- NCT03158129
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
Phase 3
Active, not recruiting
- Conditions
- Various Advanced Cancer
- Interventions
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 970
- Registration Number
- NCT03143153
- Locations
- 🇺🇸
Southern Cancer Center, Inc., Mobile, Alabama, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Hackensack Meridian Jersey Shore University Medical Center, Neptune, New Jersey, United States
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 162
- Registration Number
- NCT03138889
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇪Lungenklinik Hemer, Hemer, Germany
🇺🇸Highlands Oncology Group, PA - North Hills, Fayetteville, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath